Answers are grounded in this paper and cite their sources.
Background: Conventional pharmacotherapy for metastatic melanoma and advanced squamous cell carcinoma faces significant challenges, primarily driven by acquired resistance to BRAF/MEK inhibitors and immune checkpoint blockade failure. The PhytoIntelligence 1.9 (PI 1.9) algorithm leverages computational docking and systems biology to identify synergistic phytochemical complexes capable of multi-nodal signaling inhibition. Objective: This protocol delineates the theoretical framework and experimental validation of "Dermo-Phyt 4X," a combinatorial formulation targeting the MAPK/ERK, PI3K/AKT/mTOR, and JAK/STAT pathways simultaneously. Projected Outcomes: We hypothesize that the PI 1.9 derived formulation will demonstrate aCombination Index (CI) < 0.8 (indicating strong synergy) in A375 and SK-MEL-28 cell lines, restoring apoptotic sensitivity in chemoresistant phenotypes via the downregulation of Bcl-2 and suppression of NF-κB nuclear translocation. This protocol provides the standard operating procedures for in vitro validation and statistical power analysis for subsequent in vivo translation.
No takes yet. Share an insight, caveat, or question.
Marie Seshat Landry (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: